| Title | Engineered CRISPR/Cas13d Sensing hTERT Selectively Inhibits the Progression of Bladder Cancer In Vitro |
| Authors | Zhuang, Chengle Zhuang, Changshui Zhou, Qun Huang, Xueting Gui, Yaoting Lai, Yongqing Yang, Shangqi |
| Affiliation | Peking Univ, Dept Urol, Shenzhen Hosp, Shenzhen, Peoples R China Huazhong Univ Sci & Technol, Union Shenzhen Hosp, Dept Urol, Shenzhen, Peoples R China Univ South China, Dept Urol, Affiliated Nanhua Hosp, Hengyang, Peoples R China Shenzhen Yantian Dist Peoples Hosp, Dept Nephrorheumatol, Shenzhen, Peoples R China |
| Issue Date | 19-Mar-2021 |
| Publisher | FRONTIERS IN MOLECULAR BIOSCIENCES |
| Abstract | Aptazyme and CRISPR/Cas gene editing system were widely used for regulating gene expression in various diseases, including cancer. This work aimed to reconstruct CRISPR/Cas13d tool for sensing hTERT exclusively based on the new device OFF-switch hTERT aptazyme that was inserted into the 3' UTR of the Cas13d. In bladder cancer cells, hTERT ligand bound to aptamer in OFF-switch hTERT aptazyme to inhibit the degradation of Cas13d. Results showed that engineered CRISPR/Cas13d sensing hTERT suppressed cell proliferation, migration, invasion and induced cell apoptosis in bladder cancer 5637 and T24 cells without affecting normal HFF cells. In short, we constructed engineered CRISPR/Cas13d sensing hTERT selectively inhibited the progression of bladder cancer cells significantly. It may serve as a promising specifically effective therapy for bladder cancer cells. |
| URI | http://hdl.handle.net/20.500.11897/610049 |
| DOI | 10.3389/fmolb.2021.646412 |
| Indexed | SCI(E) |
| Appears in Collections: | 深圳医院 |
